You are browsing articles on the topic of Interventional Cardiology Archives - CardioExchange

Avatar of E Murat Tuzcu, MD

Are We Equipped to Make a CHOICE Between TAVR Devices? (31 Mar 2014)

Voices

E Tuzcu, MD

E. Murat Tuzcu offers his perspective on the CHOICE trial comparing the CoreValve and Edwards Sapien XT devices for transcatheter aortic valve replacement.

Avatar of Larry Husten, PHD

First TAVR Comparison Trial Favors Sapien XT Over CoreValve (30 Mar 2014)

News

With two devices now approved for transcatheter aortic valve replacement (TAVR), the marketing battle has begun to win the hearts and minds of cardiologists. On Saturday at the ACC, Medtronic gained bragging rights showing the first mortality benefit for its CoreValve device. A similar improvement did not occur in the PARTNER trials with the Edwards…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Ajay

TAVR: Are You Impressed Now? (29 Mar 2014)

Voices

Ajay J Kirtane, MD, SM

Interventionalist Ajay Kirtane offers his perspective on the new randomized trial comparing transcatheter (CoreValve) with surgical aortic valve replacement.

Avatar of Deepak

Negative Findings on Renal Denervation for Hypertension: Sweet SYMPLICITY? (29 Mar 2014)

Voices

Deepak L. Bhatt, MD, MPH

Deepak L. Bhatt, co-principal investigator of the SYMPLICITY HTN-3 trial, discusses the trial’s findings and their implications for clinical practice.

Avatar of Larry Husten, PHD

Survival Advantage for TAVR Over Surgery in High-Risk Patients (29 Mar 2014)

News

Transcatheter aortic valve replacement (TAVR), which has been slowly and cautiously entering the clinical arena, will probably get a big boost from a new trial showing a significant mortality advtange for TAVR over traditional surgery. Results from the U.S. CoreValve High-Risk Study were presented at the American College of Cardiology in Washington, DC, and published…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

No Benefit Found in First Real Test of Renal Denervation (29 Mar 2014)

News

SYMPLICITY HTN-3, the eagerly awaited first rigorous test of renal denervation, shows that the real effect of the novel blood-pressure-lowering technology is dramatically lower than earlier expectations, which had been fueled by data from previous uncontrolled trials. Results of SYMPLICITY HTN-3 were presented at the American College of Cardiology conference in Washington, DC, and published simultaneously…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

ACC.14 Preview: Renal Denervation, TAVR Comparisons, and More (24 Mar 2014)

News

The ACC begins this Saturday in Washington, DC. Here’s a preview of some of the most highly anticipated late-breaking clinical trials: On Saturday morning at the opening session the world will finally learn more about the failure of Symplicity HTN-3, the Medtronic trial of renal denervation. Until recently, renal denervation was thought to be an…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

rAAA Patients More Likely to Get Surgery and Survive in the U.S. Than in England (13 Mar 2014)

News

Patients with a ruptured abdominal aortic aneurysm (rAAA) have better outcomes in the United States than in England according to a new study published in the Lancet. Researchers at the University of London compared hospital data from 11,799 rAAA patients in England with 23,838 rAAA patients in the U.S. They found that U.S. patients were more likely…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Catherine

Achieving Consensus for the 2014 ACC/AHA Valvular Heart Disease Guideline (13 Mar 2014)

Voices

Catherine M. Otto, MD and Rick Akira Nishimura, MD

The writing committee co-chairs of the 2014 ACC/AHA Valvular Heart Disease Guideline discuss how the committee achieved consensus on the future treatment of valvular disease.

Avatar of Larry Husten, PHD

New Guidelines Issued for Valvular Heart Disease (3 Mar 2014)

News

The American Heart Association and the American College of Cardiology today released new practice guidelines for the management of patients with valvular heart disease (VHD). Among its most notable features, the new document provides a new system of classification for VHD and lowers the threshold for interventions, including, for the first time, transcatheter as well…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.